Regeneron Pharmaceuticals Inc. buy Evercore ISI
Summary
This prediction is currently active. The prediction currently has a performance of 17.74%. This prediction currently runs until 16.05.25. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -1.581% | -1.581% |
iShares Core DAX® | -0.372% | 5.236% |
iShares Nasdaq 100 | -1.950% | 1.680% |
iShares Nikkei 225® | -1.690% | 7.286% |
iShares S&P 500 | -0.399% | 2.379% |
Comments by Evercore_ISI for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Evercore_ISI for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
14.05.24
14.05.25
03.09.24